Press Release
27 July 2021 14:00:00 CEST

Hemply Balance signs collaboration agreement with Cannabis Delivery Sciences (CDS) for commercialization of Alginate films with CBD in Europe

Hemply Balance Holding AB (publ) ("Hemply Balance" or "the Company") has announced that its subsidiary Glowing Pine BV has signed a collaboration agreement with Cannabis Delivery Sciences for the development of alginate films with the cannabinoid CBD and the subsequent commercialization of these products under the Hemply Balance brand in Sweden and the rest of Europe.

The product development of the films is expected to take about six months and is already underway in the CDS laboratory in Uppsala. Hemply Balance is also already taking steps to prepare for market entry. The goal is to launch CBD products based on alginate films on the Swedish market in 2022.

The collaboration with CDS will enable Hemply Balance to extend its range with competitive new products that will support it throughout the upcoming expansion phase in the European market.

The technology behind the alginate film is patented by Klaria (Klaria Pharma Holding AB), which is the parent company of CDS. The technology allows the alginate film to adhere to the oral mucosa immediately after application. While the film is attached, cannabinoids are transferred directly into the blood via the oral mucosa. The film remains for about five minutes and before dissolving completely.

- Initiating this unique collaboration with CDS and its owner Klaria creates a fantastic platform for growth for Hemply Balance. The alginate films are the first of their kind and have strong patent protection, meaning that competition will be limited, says Pingis Berg-Hadenius, Chairman of the Board at Hemply Balance's.

- Scott de Mercado, Head of Business Development at Cannabis Delivery Sciences said of the collaboration agreement with Hemply Balance, “This means that we will start selling our CBD-infused alginate films in Sweden and across Europe together. This

allows Cannabis Delivery Sciences to harness the entire value chain for alginate film products with cannabinoids: from cultivating our own cannabis and hemp species in collaboration with our partner Chillam, to production and now marketing and sales of alginate films with CBD in Europe.”.

For further information, please contact:

Hemply Balance Holding
Emil Sandin
CEO
Tel: +46 (0) 720 40 80 69
E-mail: emil.sandin@hemplybalance.com

Hemply Balance Holding
Pingis Berg-Hadenius
Chairman of the Board
Tel: +46 (0) 708 32 76 57
Email: hadenius@economista.se

Cannabis Delivery Sciences
Scott de Mercado
Head of Business Development
Tel: +46 (0) 72 307 88 73
Email: scott.demercado@candelsci.com

About Hemply Balance
Hemply Balance Holding AB (publ) is a health food company that sells safe, high-quality hemp products for intimate and personal care, as well as hemp oil and hemp capsules outside Sweden. The company's goal is to consolidate its position as the leading player in high-quality hemp products in Sweden and to become a significant player in Europe.

About Cannabis Delivery Sciences
CDS is a cannabis-focused drug delivery company with a patent-protected proprietary technology. They make oral films with cannabinoids that deliver a fast and precise dose of cannabis. The films are based on alginate polymers extracted from brown algae (kelp) in the North Sea and harvested from sustainable kelp forests. CDS is a subsidiary of Klaria Pharma AB, which holds the patents for the alginate film technology.

For more information, visit: https://cannabisdeliverysciences.com/

About Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, fast-acting products. By combining a patented technology - a film that adheres to the oral mucosa - with proven active substances, the company has created a concept for drug distribution with a multitude of benefits and many possible uses. Klaria is listed on the First North Growth Market under the short name KLAR. FNCA Sweden is a Certified Advisor (info@fnca.se, 08-528 00 399) for Klaria Pharma Holding AB. For more information, visit www.klaria.com.

Augment Partners AB, tel. +46 8 604 22 55, email: info@augment.se is the company's Mentor.

For more information, visit the Hemply Balance website www.hemplybalance.com

This information is information that Hemply Balance Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-07-27 14:00 CEST.